

4. Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. *Intensive Care Med* **2000**;26:1390–4.
5. Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem/cilastatin: worldwide clinical experience based on 3470 patients. *J Antimicrob Chemother* **1986**;18(Suppl E): 193–202.

The views expressed in this letter are those of the authors and do not reflect the official policy or position of the US Navy, the US Army, or the US Department of Defense.

Reprints or correspondence: Dr. Kyle Petersen, Division of Infectious Diseases, National Naval Medical Center, 8901 Wisconsin Ave., Bethesda, MD 20889 (knpetersen@bethesda.med.navy.mil).

Clinical Infectious Diseases 2004;39:1866–7

© 2004 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2004/3912-0023\$15.00

Limits to the Use of the Procalcitonin Level as a Diagnostic Marker

SIR—The comparison by Simon et al. [1] of the accuracy of serum C-reactive protein levels and procalcitonin levels for the diagnosis of bacterial infections is most interesting. Three important points, however, merit comment.

First, with regard to the source of procalcitonin, recent findings have revealed that, in marked inflammation, and especially in systemic infection [2], the calcitonin (*CT*) gene is ubiquitously expressed in *parenchymal* cells. Thus, the expression of the *CT* gene is not limited to liver or leukocyte cells. Furthermore, in leukocytes, *CT* gene expression is only very limited and transient [3]. No *CT* gene expression is found if these cells are harvested from patients who have sepsis and markedly elevated serum procalcitonin levels. In whole blood, lipopolysaccharide stimulation is unable to induce any detectable procalcitonin production by leukocytes. Moreover, the observation that some patients with sepsis have high serum procalcitonin levels even after near-complete eradication of their leukocyte population by chemotherapy suggests that these cells are not a major source of procalcitonin. Parenchymal cells (including liver, kidney, and muscle cells and adi-

pocytes) constitute the largest mass of tissue and the principal source of circulating procalcitonin in patients with sepsis [4]. Procalcitonin, a prototype of *hormokine* mediators, can follow either a classical hormonal expression pathway or, alternatively, a cytokine-like expression pathway. The ubiquitous production of this *hormokine* is triggered by microbial toxins (e.g., lipopolysaccharides) together with mediators from humoral or cell-mediated host responses (e.g. IL-1b and TNF- α). These findings are relevant, as they are the basis for the superior diagnostic accuracy of procalcitonin levels, compared with C-reactive protein levels, as is shown in the excellent meta-analysis of Simon et al. [1].

Second, for the appropriate use of a marker in a clinical setting, the *functional* assay sensitivity is more relevant than the reported detection limit. The commercially available 2-site assay (LUMItest PCT; distributed by Brahms) used by Simon et al. [1] is useful to detect markedly elevated procalcitonin levels in patients with severe systemic bacterial infection or sepsis. However, this assay has the disadvantage of relative insensitivity, with a functional detection limit of 0.5 ng/mL procalcitonin. On the basis of measurements made with an ultrasensitive research assay, a study found that 30 healthy donors had a mean procalcitonin level (\pm SD) of 0.03 ± 0.02 ng/mL [5]. Thus, the LUMItest assay is not sensitive enough to detect mildly or moderately elevated procalcitonin levels, which limits its diagnostic use in conditions other than overt sepsis. For research purposes, more-sensitive procalcitonin assays have been described [5].

Last, any observational study investigating the diagnostic accuracy of a given marker is biased by the choice of the “gold standard.” As Simon et al. [1] correctly state, this standard does not exist with respect to infection, and thus all studies are prone to potential bias. Importantly, interventional studies in which the antimicrobial therapy is guided by the marker

and the “gold standard” for diagnosis is the *outcome* have the potential to resolve this dilemma. With respect to procalcitonin levels, initial studies of lower respiratory-tract infections and meningitis have shown promising results [6, 7]. The time has arrived for investigators to conduct more intervention studies for other sites of infection, using more-sensitive procalcitonin assays to tackle the vicious cycle of antibiotic overuse and emerging multidrug resistance.

Acknowledgments

Potential conflicts of interest. B.M. has received research support and honoraria from Brahms AG related to advisory board activities and talks. All other authors: no conflicts.

Beat Müller,¹ Mirjam Christ-Crain,¹
Eric S. Nylén,² Richard Snider,^{2,3}
and Kenneth L. Becker^{2,3}

¹Department of Internal Medicine, University Hospitals, Basel, Switzerland; and ²Department of Medicine, George Washington University School of Medicine, and ³Veterans Affairs Medical Center, Washington, D.C.

References

1. Simon L, Gauvin F, Anre K, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. *Clin Infect Dis* **2004**;39:206–17.
2. Becker KL, Nylén ES, White JC, Müller B, Snider RH. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. *J Clin Endocrinol Metab* **2004**;89:1512–25.
3. Linscheid P, Schaer DJ, Seboek D, Zulewski H, Keller U, Müller B. Transient expression of procalcitonin and the vasodilating neuropeptide CGRP upon monocyte-adhesion. *Crit Care Med* **2004**;32:1715–21.
4. Linscheid P, Seboek D, Nylén ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. *Endocrinology* **2003**;144:5578–84.
5. Nylén E, Muller B, Becker KL, Snider R. The future diagnostic role of procalcitonin levels: the need for improved sensitivity. *Clin Infect Dis* **2003**;36:823–4.
6. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided therapy on antibiotic use and outcome in lower respiratory tract infections: cluster-randomized, single-blinded trial. *Lancet* **2004**;363:600–7.
7. Marc E, Menager C, Moulin F, et al. Procal-

citonin and viral meningitis: reduction of unnecessary antibiotics by measurement during an outbreak. *Arch Pediatr* **2002**;9:358–64.

Reprints or correspondence: Dr. Beat Müller, Dept. of Internal Medicine, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland (bmueller@uhbs.ch).

Clinical Infectious Diseases 2004;39:1867–8

© 2004 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2004/3912-0024\$15.00